The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of eye cancer — the company announced in a press release.
Publications
The Paradoxical Behavior of microRNA-211 in Melanomas and Other Human Cancers
Cancer initiation, progression, and metastasis leverage many regulatory agents, such as signaling molecules, transcription factors, and regulatory RNA molecules.
Impact of the time interval between primary melanoma excision and sentinel node biopsy: A systematic review and meta-analysis
Researchers conducted this systematic review and meta-analysis to assess the connection between time from biopsy to sentinel-node biopsy (SLNB) and patients’ outcomes for melanoma.
Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin
The recent coronavirus disease 2019 (COVID-19) pandemic has created a quandary for the physician in terms of evaluating and treating cutaneous skin cancers, particularly melanomas.